由于利奈唑利(linezonid)用于治疗革兰阳性菌感染的末期肾病的疗效和耐受性数据不足,作者采用对照研究,比较其治疗革兰阳性菌感染的末期肾病病例和非末期肾病病例,观察两组疗效和耐受性的差异。研究病例中男性58例,女性33例,平均年龄61.5岁(45.4～81.2岁)。其中28例(30.8%)开 Due to insufficient data on the efficacy and tolerability of linezonid in the treatment of Gram-positive bacterial infections of the terminal nephropathy, the authors compared the efficacy and tolerability of linezonid in the treatment of Gram-positive bacterial infections with end-stage and end-stage renal disease, To observe the differences between the two groups of efficacy and tolerability. The study included 58 males and 33 females, with an average age of 61.5 years (45.4-81.2 years). Among them, 28 cases (30.8%) were open